​Cayman Chemical’s medicinal chemistry program developed a series of over 300 small molecule difluorolactam full agonists of the EP₄ receptor and identified KMN-159 as an early lead compound. KMN-159 is very stable and has increased binding selectivity for EP₄ over other EP receptors, excellent potency for activation of EP₄, and desirable pharmacological properties. KMN-159 also induces the differentiation of human and rat bone marrow stem cells, independent of the age or sex of the donor, as measured by the dose-dependent induction of cellular, biochemical, and molecular markers of osteoblastogenesis.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Owen, T., Patel, C., Wei, S., et al. A novel selective EP₄ prostaglandin receptor agonist, KMN-159, induces osteogenesis in bone marrow stem cells. Poster presented at: MichBio's 2019 Cutting Edge / Drug Discovery & Development in Michigan Symposium; November 12, 2019; Ann Arbor, MI.